Literature DB >> 15122326

E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.

Martin Oeggerli1, Sanja Tomovska, Peter Schraml, Daniele Calvano-Forte, Salome Schafroth, Ronald Simon, Thomas Gasser, Michael J Mihatsch, Guido Sauter.   

Abstract

E2F3 is located in the 6p22 bladder amplicon and encodes a transcription factor important for cell cycle regulation and DNA replication. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (P < 0.0001 each). None of 272 pTaG1/G2 tumors, but 35 of 311 pT1-4 carcinomas (11.3%), had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (P < 0.0001 each). To evaluate whether E2F3 expression correlates with tumor proliferation, the Ki67 labeling index (LI) was analysed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (P < 0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122326     DOI: 10.1038/sj.onc.1207749

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Authors:  C D Hurst; D C Tomlinson; S V Williams; F M Platt; M A Knowles
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

Review 3.  Proapoptotic role of novel gene-expression factors.

Authors:  J V Tapia-Vieyra; P Ostrosky-Wegman; J Mas-Oliva
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.405

4.  APC/C (Cdh1) controls the proteasome-mediated degradation of E2F3 during cell cycle exit.

Authors:  Zhen Ping; Ratna Lim; Tarig Bashir; Michele Pagano; Daniele Guardavaccaro
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

Review 5.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

6.  E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity.

Authors:  P S Danielian; L B Friesenhahn; A M Faust; J C West; A M Caron; R T Bronson; J A Lees
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

Review 7.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

8.  Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3.

Authors:  Julian C Lui; Jeffrey Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

9.  Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.

Authors:  Carl D Morrison; Pengyuan Liu; Anna Woloszynska-Read; Jianmin Zhang; Wei Luo; Maochun Qin; Wiam Bshara; Jeffrey M Conroy; Linda Sabatini; Peter Vedell; Donghai Xiong; Song Liu; Jianmin Wang; He Shen; Yinwei Li; Angela R Omilian; Annette Hill; Karen Head; Khurshid Guru; Dimiter Kunnev; Robert Leach; Kevin H Eng; Christopher Darlak; Christopher Hoeflich; Srividya Veeranki; Sean Glenn; Ming You; Steven C Pruitt; Candace S Johnson; Donald L Trump
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

10.  E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma.

Authors:  Li Chen; Jian Hua Yu; Zhi Hui Lu; Wei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.